Compare Eli Lilly And Co (LLY) vs Tesla, Inc. (TSLA) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Tesla trades at $379.74, down 0.29% on the day, with bearish technical signals dominating despite recent earnings beats. The stock shows elevated valuation ratios (P/E 339, P/S 13.3) while profitability metrics have weakened, with net income margin declining to 3.95% in 2025. Recent news highlights regulatory approval for Tesla's driver assistance software in Europe and a strategic pivot toward robotics and AI amid slowing auto business growth.

Tesla faces near-term headwinds from competitive pressures and valuation concerns, but maintains strong institutional support with a $409 consensus price target. The company's expansion into autonomous driving and energy storage represents long-term growth potential, though execution risks and margin compression remain key challenges for investors.